Good
Partially Aligned
Patient Risk:
Low
Summary
Most clinical and mechanism claims about VENTOLIN HFA (albuterol sulfate) indications and beta2-agonist mechanism match the provided FDA label excerpts. However, several non-label claims about Philippines pricing/availability and patent databases are not supported by the provided prescribing information.
Category Scores
Accurate Statements
Ventolin contains the active ingredient albuterol sulfate.
Description (11): active component of VENTOLIN HFA is albuterol sulfate, USP; also 1: Ventolin HFA indication tied to albuterol sulfate.
Ventolin is a bronchodilator medication.
12.1 Mechanism of Action: Activation of beta2-adrenergic receptors on airway smooth muscle leads to relaxation; 1.1/1.2 indicate treatment/prevention of bronchospasm.
Ventolin is used to relieve bronchospasm in adults and children aged 4 years and older who have reversible obstructive airway disease.
1.1 Bronchospasm: indicated for treatment of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease.
Ventolin is used to prevent exercise-induced bronchospasm in patients aged 4 years and older.
1.2 Exercise-Induced Bronchospasm: prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.
Albuterol sulfate is a short-acting beta2-adrenergic agonist.
Not explicitly stated in the provided excerpts; however VENTOLIN HFA is described as a beta2-adrenergic agonist in Warnings (5.4) and Mechanism of Action (12.1). Short-acting is not stated in the supplied text.
Albuterol sulfate works by relaxing the muscles in the airways.
12.1 Mechanism of Action: activation on airway smooth muscle leads to relaxation; albuterol relaxes smooth muscles of all airways.
The safety and effectiveness of VENTOLIN HFA for treatment or prevention of bronchospasm and for prevention of exercised-induced bronchospasm in pediatric patients aged 4 years and older have been established.
8.4 Pediatric Use: safety/effectiveness established for patients aged 4 years and older.
Unsupported Statements
Ventolin nebules are priced in the Philippines generally ranging from PHP 400 to PHP 600 for a box of 20 units.
No pricing information for Ventolin nebules (or any drug) is present in the provided FDA prescribing information excerpts.
Ventolin nebules are widely available in most licensed pharmacies across the Philippines.
No statements about geographic availability or pharmacy distribution are present in the provided FDA prescribing information excerpts.
Other brands containing albuterol sulfate are available as inhalation solutions for nebulization.
The provided labeling excerpts do not mention other brands or nebulized inhalation solution availability.
Information on specific patent expirations for Ventolin nebules can be found on specialized databases such as DrugPatentWatch.com.
The provided FDA prescribing information excerpts do not discuss patent-expiration resources or any specific database.
Patent status is crucial for determining when generic versions of a drug might become available, potentially influencing pricing.
The provided FDA prescribing information excerpts do not discuss patent status, generic availability timelines, or pricing determinants.
Contradictions
Important Omissions
Ventolin HFA administration instructions (e.g., priming before first use, route of administration only by oral inhalation, cleaning/actuator washing) were not addressed in the AI claims even though the user list includes clinical/mechanism claims.
Importance:
Low
Dosing frequency/timing details from the label for bronchospasm and exercise-induced bronchospasm were not included (the user claims state indication/purpose and age but not the specific dosing regimen).
Importance:
Moderate
Safety warnings/precautions (e.g., paradoxical bronchospasm, deterioration of asthma, do not exceed recommended dose, hypersensitivity, hypokalemia, cardiovascular effects) were not mentioned in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The on-label clinical indication and mechanism statements align with the provided excerpts. The unsupported statements relate to pricing/availability/patents and are not directly prescribing claims, but dosing/safety precaution details were omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Non-label claims about Philippines pricing/availability and patent database/generic/patent implications are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict statements to the provided prescribing information (e.g., indication and mechanism). Remove or clearly separate non-prescribing claims (pricing, availability, patent databases) because they are not addressed in the FDA label excerpts.